A subset of patients with advanced castration-resistant prostate cancer may eventually
evolve into an androgen receptor (AR)–independent phenotype, with a clinical picture …

Various preclinical models have been developed to clarify the pathophysiology of prostate
cancer (PCa). Traditional PCa cell lines from clinical metastatic lesions, as exemplified by …

Androgen receptor (AR) signaling is a distinctive feature of prostate carcinoma (PC) and
represents the major therapeutic target for treating metastatic prostate cancer (mPC) …

Cancers adapt to increasingly potent targeted therapies by reprogramming their phenotype.
Here we investigated such a phenomenon in prostate cancer, in which tumours can escape …

Mechanisms controlling the emergence of lethal neuroendocrine prostate cancer (NEPC),
especially those that are consequences of treatment-induced suppression of the androgen …

Purpose: Clinical features characteristic of small-cell prostate carcinoma
(SCPC),“anaplastic,” often emerge during the progression of prostate cancer. We sought to …

The incidence of aggressive neuroendocrine prostate cancers (NEPC) related to androgen-
deprivation therapy (ADT) is rising. NEPC is still poorly understood, such as its …

Standardized and reproducible preclinical models that recapitulate the dynamics of prostate
cancer are urgently needed. We established a bank of transplantable patient-derived …

Despite advances in the development of highly effective androgen receptor (AR)-directed
therapies for the treatment of men with advanced prostate cancer, acquired resistance to …

Purpose: Small cell neuroendocrine carcinoma of the prostate is likely to become
increasingly common with recent advances in pharmacologic androgen suppression. Thus …